Patents Represented by Attorney, Agent or Law Firm Michael A. Gollin
-
Patent number: 6772229Abstract: A system for communicating information among participants in a distributed application having peripheral communications devices comprises a central agent having two-way links to the peripheral devices, a notice generator triggered by an information input from one participant directed to at least one other participant, the notice generator generating a notice for the other participant(s) and pushing the notice to the peripheral device of the other participant(s) only if the information input was directed to the other participant(s), a central storage medium storing the information input, and an access channel by which the other participant(s) may receive the information input only if the other participant(s) responds to the notice. The links may form a computer network, cable network, telecommunications network, wireless network, or other network, or a combination. Additional information inputs may be associated with the first information input or may modify or delete it.Type: GrantFiled: November 13, 2000Date of Patent: August 3, 2004Assignee: GroupServe, Inc.Inventors: Theodore B. Achacoso, D. Wayne Silby
-
Patent number: 6767932Abstract: This invention relates to methods and apparatus for producing a discretely striped, multi-property foam and the products and articles produced thereby. The invention provides a pre-foam stream at a first pressure and intermittently injects at least one additive into the pre-foam stream at a pressure higher than the first pressure, providing a laminar flow pre-foam stream with alternating segments having different properties. The pre-foam stream is poured onto a surface and cures into a discretely striped foam product which may be used for many purposes such as but not limited to padding, clothing, toys, or bedding.Type: GrantFiled: June 6, 2001Date of Patent: July 27, 2004Assignee: Wm. T. Burnett & Co.Inventors: George J. Tolen, David J. Kelly
-
Patent number: 6756379Abstract: Methods of providing neuroprotection are disclosed comprising administering a non-sedative barbiturate compound in an amount sufficient to achieve neuroprotection in a mammalian subject. Preferred compounds are in the family of diphenylbarbituric acid and analogs.Type: GrantFiled: January 27, 2003Date of Patent: June 29, 2004Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Daniel A. Moros, Barrie Levitt, Avraham Yacobi
-
Patent number: 6747068Abstract: The invention is a hydrophobic polyurethane foam prepared from a conventional PO/EO polyether polyol, a graft polyol and a hydrophobicity inducing surfactant. The foam is sufficiently hydrophobic to pass a stringent water impermeability test.Type: GrantFiled: February 15, 2001Date of Patent: June 8, 2004Assignee: Wm. T. Burnett & Co.Inventor: David J. Kelly
-
Patent number: 6745919Abstract: An article of manufacture comprises a) a squeezable bottle having an outlet, b) a plug in the bottle, the plug comprising an upper surface with a protruding nipple having a neck, and a top and an orifice communicating with a smooth tubular channel sized to permit a semi-solid formulation to be squeezed out of the bottle and through the channel and orifice without dislodging the cap, the neck of the nipple having a protruding height slightly greater than the thickness of a spoon, and the neck of the nipple and the flat upper surface forming a notch which engages with the edge of a spoon, the orifice forming a sharp intersection with the top of the nipple sufficient to cut flow of the formulation cleanly when pressure ceases, and the junction of the top of the nipple with the nipple neck having a bevel, and c) a child resistant cap to cover the orifice when the formulation is not in use, the cap sealing the orifice without abrading the nipple.Type: GrantFiled: October 22, 2002Date of Patent: June 8, 2004Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Daniel A. Moros, Satish Asotra, Theophilus van den Heuvel
-
Patent number: 6673944Abstract: The invention provides a method for the direct preparation of pure warfarin sodium from warfarin acid. The reaction is conducted in a polar organic solvent, preferably ethanol, using a volatilizable base, preferably sodium bicarbonate or sodium carbonate, at low temperature. Drying the final product is accomplished at low temperature to avoid decomposition of the final warfarin sodium product.Type: GrantFiled: February 28, 2001Date of Patent: January 6, 2004Assignee: Taro Pharmaceutical Industries, Ltd.Inventors: Michel Ashkar, Sorin Bercovici, Robert Graff
-
Patent number: 6656217Abstract: The aggregation of platelets on the surface of a foreign body exposed to the flowing blood of a living being (such as plastic tubing, a balloon or the end of a catheter surgically inserted in a blood vessel, a stent implanted therein or synthetic grafts, which surface normal promotes such platelet aggregation to form a coating firmly affixed to that surface which would restrict the flow of blood past that surface or to form a blood clot detachable from that surface), is inhibited by a gas permeable coating on the surface of a physiologically acceptable polymer as which contains dissolved or dispersed therein a nitrosyl-containing organometallic compound, such as sodium nitroprusside, which is protected from diffusion from the coating and from direct contact with the blood and which slowly decomposes at the body temperature within the coating and in so doing releases a platelet aggregation-inhibiting amount of nitric oxide which diffuses from the coating during the period when platelet aggregation by the surfaType: GrantFiled: March 1, 1999Date of Patent: December 2, 2003Assignee: NovoVascular, Inc.Inventors: William R. Herzog, Jr., Sovitj Pou, Gerald M. Rosen, Yi-Ju Zhao
-
Patent number: 6656482Abstract: A spill-resistant pharmaceutical formulation for oral administration from a squeezable container comprises a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent, the formulation consisting of mutually compatible components and having the following properties: a viscosity within the range of about 7500 to about 12,500 cps using a Brookfield Viscometer with a ‘C’ spindle with Helipath movement at a spindle speed of 10 rpm and 20-25° C., a viscometric yield value of a semi-solid, a spill-resistant consistency permitting the composition to be squeezed by light manual pressure through a channel, to spread in a spoon bowl sufficiently quickly for accurate measurement, and to remain in the spoon bowl without spilling on spoon inversion, tilting at 90 degrees, and vibration, homogeneity such that the components do not separate under conditions of use, and a storage stability such that the foregoing properties are retained for at least two years shelf life.Type: GrantFiled: January 23, 2002Date of Patent: December 2, 2003Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Rakesh Mehta, Dan Moros
-
Patent number: 6623676Abstract: A continuous process for reusing scrap polyurethane involves the following stages: Chips of thermoset polyurethane foam are supported as a bed; the bed of chips while moving is heated; the bed of chips while moving is subjected to pressure or compression; and a web is formed. The resulting material is useful in many industrial applications, including padding, gaskets, and insulation.Type: GrantFiled: July 14, 1999Date of Patent: September 23, 2003Assignee: Wm. T. Burnett & Co.Inventors: Gregory B. Davis, Walter Greenhouse, George Tolen
-
Patent number: 6610862Abstract: The present invention is a method for producing warfarin sodium from warfarin sodium 2-propanol clathrate by thermal, nondestructive solvent expulsion. The solvent expulsion is conducted under conditions of controlled heat transfer whereby the 2-propanol is expelled from the warfarin sodium 2-propanol clathrate without decomposition of warfarin sodium or the clathrate. Heating is conducted the clathrate at a temperature from about 100° C. to about 170° C. in an active oven under air or in an inert atmosphere and at partial pressures ranging from that of a relative vacuum to atmospheric pressure. The invention also relates to pure warfarin sodium prepared according to the method of the invention and pharmaceutical compositions containing warfarin sodium.Type: GrantFiled: February 28, 2001Date of Patent: August 26, 2003Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Sorin Bercovici, Shimon Chernyak, Konstantin Ulanenko
-
Patent number: 6610016Abstract: Coatings to enhance the echogenicity of materials are especially useful for medical devices wherein the practitioner desires to locate or visualize a device by ultrasonic imaging when the device is inserted into a body cavity. These coatings can be applied to any device of virtually any composition. To accomplish this, a polymer matrix is formed containing an entrapped gas in enclosed bubbles or open surface channels or cavities. Coated needles are visible in ultrasound when inserted in animals. A pre-coat or base coat may be applied to condition the surface to enhance adhesion. A finish coat or top coat may be applied to improve durability, smoothness, and biocompatibility, lubricity, antibiotic, antimicrobial, antithrombogenic activity, and other desirable properties for the finished product. Coating liquids and methods for preparing and applying such coatings are disclosed, including forming bubbles by chemical reaction during the coating process.Type: GrantFiled: August 4, 1999Date of Patent: August 26, 2003Assignee: STS Biopolymers, Inc.Inventors: Michael R. Violante, Richard J. Whitbourne, John F. Lanzafame, Margaret Lydon
-
Patent number: 6552053Abstract: The invention provides a method for modulating attentive cognition comprising administering a compound that alters intraneuronal carbonic anhydrase activity thereby affecting establishment of a theta rhythm. The metabolic pathway of the compound preferably involves bicarbonate-mediated GABAergic depolarization. The term “attentive cognition” is meant to encompass memory formation, learning, spatial memory, and attention. The modulating may be stimulating, or the compound may have the multiple effects of inhibiting intraneuronal carbonic anhydrase activity, establishment of a theta rhythm, and memory acquisition. The invention further provides a method of modulating memory and attention comprising switching theta rhythm on and off, the switching comprising potentiating or inhibiting intraneuronal carbonic anhydrase activity.Type: GrantFiled: June 7, 2001Date of Patent: April 22, 2003Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventors: Miao-Kun Sun, Daniel L. Alkon, Wei-Qin Zhao
-
Patent number: 6512005Abstract: An improved procedure for the purification of warfarin acid. Sodium, potassium and lithium warfarin salts and the corresponding clathrates are prepared in high, pharnacopeial grade purity and good yields from the pure warfarin acid and the respective metal salt bases in suitable media.Type: GrantFiled: February 28, 2001Date of Patent: January 28, 2003Assignee: Taro Pharmaceutical Industries, Ltd.Inventors: Sorin Bercovici, Yuval Evron, Osvaldo Fuxman, Mirela Jakoel, Sbar Sasson, Konstantin Ulanenko
-
Patent number: 6486152Abstract: A therapeutic formulation comprises a topically acceptable semisolid vehicle and carbamazepine, the vehicle consisting of components that are compatible with the carbamazepine, and the carbamazepine being in a concentration sufficient to permit a therapeutically effective amount of the carbamazepine to be absorbed from the formulation into the skin of a patient. The vehicle may be a cream, ointment, or gel. A method of treating a skin condition of a patient such as psoriasis comprises applying carbamazepine topically to the patient's skin until the condition improves. A method of administering carbamazepine to a patient comprises applying a formulation comprising carbamazepine topically to the patient's skin.Type: GrantFiled: June 19, 2000Date of Patent: November 26, 2002Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Marc Coles, Gad Keren
-
Patent number: 6399079Abstract: A spill-resistant pharmaceutical formulation for oral administration from a squeezable container comprises a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent, the formulation consisting of mutually compatible components and having the following properties: a viscosity within the range of about 7500 to about 12,500 cps using a Brookfield Viscometer with a ‘C’ spindle with Helipath movement at a spindle speed of 10 rpm and 20-25° C., a viscometric yield value of a semi-solid, a spill-resistant consistency permitting the composition to be squeezed by light manual pressure through a channel, to spread in a spoon bowl sufficiently quickly for accurate measurement, and to remain in the spoon bowl without spilling on spoon inversion, tilting at 90 degrees, and vibration, homogeneity such that the components do not separate under conditions of use, and a storage stability such that the foregoing properties are retained for at least two years shelf life.Type: GrantFiled: April 13, 2000Date of Patent: June 4, 2002Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Rakesh Mehta, Dan Moros
-
Patent number: 6355258Abstract: A spill-resistant pharmaceutical formulation for oral administration from a squeezable container comprises a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent, the formulation consisting of mutually compatible components and having the following proper ties: a viscosity within the range of about 7500 to about 12,500 cps using a Brookfield Viscometer with a ‘C’ spindle with Helipath movement at a spindle speed of 20 rpm and 20-25° C., a viscometric yield value of a semi-solid, a spill-resistant consistency permitting the composition to be squeezed by light manual pressure through a channel, to spread in a spoon bowl sufficiently quickly for accurate measurement, and to remain in the spoon bowl without spilling on spoon inversion, tilting at 90 degrees, and vibration, homogeneity such that the components do not separate under conditions of use, and a storage stability such that the foregoing properties are retained for at least two years shelf life.Type: GrantFiled: April 13, 2000Date of Patent: March 12, 2002Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Rakesh Mehta, Dan Moros
-
Patent number: 6346547Abstract: Low-toxicity, highly-bioavailable, pharmaceutical antioxidant compositions for preferred oral administration to mammals are provided which have at least one amino acid-based compound of the general formula (I): A—N(Z)—CH(R1)C(O)—Q (I) wherein A is represented by the formula: XO—[C(R2)2]n— wherein n is an integer of from 1 to about 3, X is selected from the group consisting of a hydrogen atom, an acyl group and a halogenated acyl group and each R2 is independently selected from the group consisting of a hydrogen atom, an alkyl group having from 1 to about 3 carbon atoms, a hydroxyalkyl group having from 1 to about 3 carbon atoms, and CH2OX; Z is selected from the group consisting of a hydrogen atom, an alkyl group of from 1 to about 3 carbon atoms, and A; R1 is an amino acid side chain group or an amino acid side chain group which forms with R2 a single heterocyclic structure having a total of from 5 to 7 atoms in the ring; and wherein Q is a substituent sType: GrantFiled: February 8, 2000Date of Patent: February 12, 2002Assignee: Checkpoint, Genetics, Inc.Inventor: Nathan Tzodikov
-
Patent number: 6333171Abstract: The present invention relates to compositions and methods for the expression of nucleic acids or polypeptides into mature T lymphocytes. The invention relates more specifically to methods of selective gene expression into mature T lymphocytes, based on CD4-derived regulatory sequences, such as CD4-derived enhancer sequences. The invention is particularly suited for regulating gene expression into mature T lymphocytes in vitro, ex vivo or in vivo, upon genetic modification of hematopoietic precursors and maturation thereof.Type: GrantFiled: January 16, 1998Date of Patent: December 25, 2001Assignee: Universite Pierre et Marie CurieInventors: David Klatzmann, Patrick Salmon, Olivier Boyer
-
Patent number: 6329000Abstract: This invention discloses a kind of pine needle extract. The extract can be used to treat the following diseases: hypertension, coronary heart disease, angina pectoris, arrhythmia, diabetes, hyperlipemia, high blood viscosity, high blood aggregation, scleratheroma, cerebral infarction, brain scleratheroma, senile dementia, sudden deafness, etc.Type: GrantFiled: October 1, 1999Date of Patent: December 11, 2001Inventor: Ling Ji
-
Patent number: D480960Type: GrantFiled: August 22, 2002Date of Patent: October 21, 2003Assignee: Mixtek System LLCInventors: Richard Gray, Christopher Mears, Joel Wittkamp